Live zoster vaccine,
does it really help with Reduction or delay of new dementia diagnoses in older adults?
research showsThe grade is B. A regression-discontinuity natural experiment based on the Welsh eligibility birth-date cutoff estimated that live zoster vaccination reduced new dementia diagnoses over seven years by 3.5 percentage points, 95% CI 0.6 to 7.1. This was not a randomized trial; it relies on continuity across the cutoff and absence of another factor changing abruptly on the same date.
ads claimThe result should not be generalized to all zoster vaccines, recombinant vaccine, or every age group.
Useful facts when choosing a product
- The exposure was live-attenuated Zostavax, not recombinant Shingrix.
- Dementia was ascertained from coded electronic health records rather than uniform clinical re-examination.
- Funding came from the Stanford Knight Initiative, NIA, NIAID, and Chan Zuckerberg Biohub; the authors declared no competing interests.
What the research actually shows
Eyting and colleagues analyzed 282,541 people without prior dementia; 35,307 received a new diagnosis during seven years. The figures 14.0% and 17.5% were reconstructed by combining the reported 3.5-point absolute difference and 20.0% relative reduction; they were not observed arm-specific incidence rates and are not used as evidence. The Australian natural experiment reported an eligibility effect of -1.8 points over 7.4 years, and a 2026 Ontario analysis of 232,124 people reported -2.0 points over 5.5 years. These are different-country and different-data-source replications, but overlapping coauthors including Pascal Geldsetzer mean they are not independent-team replications. Verdict 651 is B with 79 points, but it concerns recombinant vaccine prevention of shingles and postherpetic neuralgia, a different vaccine and endpoint.
Why this is classified as B (76)
A large publicly and philanthropically funded natural experiment measured a hard clinical diagnosis and was positive, but independent replication was not confirmed, giving B with 76 points.
Counterpoint. Associational cohorts and same-team international analyses support direction but do not satisfy independent replication.
Rejudgment record. Cross-check applied — Seven-year coded dementia outcome in the Welsh birth-date regression-discontinuity natural experiment with explicit replication audit
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced new dementia diagnoses over seven years after live vaccination | B | The Welsh natural experiment estimated a 3.5-point reduction. |
| Dementia prevention with recombinant zoster vaccine | ? | This live-vaccine result does not grade recombinant vaccine. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Fuzzy regression-discontinuity natural experiment using a birth-date eligibility cutoff | 35,307 | Stanford Knight Initiative, US NIA, NIAID, and Chan Zuckerberg Biohub | New coded dementia diagnosis within seven years | Effect of receipt -3.5 points, 95% CI -7.1 to -0.6; 20.0% relative reduction; 14.0% versus 17.5% was reconstructed from those estimates | Decisive natural experiment |
| Study 2 | Birth-date eligibility regression-discontinuity quasi-experiment | 18,402 | The detailed funding statement was not confirmed in the accessible record | New primary-care dementia diagnosis over 7.4 years | Eligibility effect -1.8 points, 95% CI -3.3 to -0.4 | Supportive evidence not counted as independent replication because a senior author overlapped |
| Study 3 | Population-based regression-discontinuity natural experiment | 232,124 | Detailed funding was not confirmed; coauthors overlapped with the original research team | Dementia occurrence over 5.5 years | Dementia -2.0 points, 95% CI -3.5 to -0.4 | Different-data-source replication, but not independent-team replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-06).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-06 · Corrections: none
Cite this verdict
[Chamgap] Live zoster vaccine x incident dementia — Evidence Grade B·76. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/live-zoster-vaccine-incident-dementia/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.